1. Home
  2. TMCI vs CRDF Comparison

TMCI vs CRDF Comparison

Compare TMCI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$1.76

Market Cap

120.4M

Sector

Health Care

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.63

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMCI
CRDF
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
130.7M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
TMCI
CRDF
Price
$1.76
$1.63
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$4.77
$9.63
AVG Volume (30 Days)
860.9K
717.9K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$212,690,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.59
49.61
52 Week Low
$1.17
$1.48
52 Week High
$7.78
$4.56

Technical Indicators

Market Signals
Indicator
TMCI
CRDF
Relative Strength Index (RSI) 50.09 44.32
Support Level $1.24 $1.51
Resistance Level $2.25 $1.68
Average True Range (ATR) 0.21 0.09
MACD -0.00 0.01
Stochastic Oscillator 32.50 24.07

Price Performance

Historical Comparison
TMCI
CRDF

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: